

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Hodgson Ian</u> (Last) (First) (Middle) <u>C/O CORBUS PHARMACEUTICALS HOLDINGS, INC</u> <u>500 RIVER RIDGE DRIVE</u> (Street) <u>NORWOOD MA 02062</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/13/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>Corbus Pharmaceuticals Holdings, Inc. [CRBP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Operating Officer</u>	
		5. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.0001 per share	1,234	D	
Common Stock, par value \$0.0001 per share	24,743 ⁽¹⁾⁽²⁾⁽³⁾	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock options (right to buy)	(4)	11/04/2032	Common Stock	3,333	3.81	D	
Stock options (right to buy)	(5)	02/13/2033	Common Stock	1,985	4.26	D	
Stock options (right to buy)	(6)	02/16/2034	Common Stock	5,000	23.1	D	
Stock options (right to buy)	(7)	01/31/2035	Common Stock	60,000	9.79	D	

Explanation of Responses:

1. On February 13, 2023, the Reporting Person was granted 1,985 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value \$0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on February 13, 2024. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
2. On February 16, 2024, the Reporting Person was granted 5,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value \$0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 31, 2026. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
3. On January 31, 2025, the Reporting Person was granted 20,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value \$0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 31, 2026. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
4. An option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on October 10, 2023 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 10, 2023.
5. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
6. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 16, 2025 with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 16, 2025.
7. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 31, 2026, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 28, 2026.

/s/ Meghan Houghton, attorney-in-fact for Ian Hodgson 03/18/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Yuval Cohen, Ph.D., Sean Moran and Meghan Houghton his true and lawful attorney-in-fact to:

1. execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder;
2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Schedules 13D or 13G, Form ID application for EDGAR codes, and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and
3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including, without limitation, the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedules 13D and 13G and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Exchange Act and the rules thereunder with respect to the undersigned's holdings of and transactions in securities issued by Corbus Pharmaceuticals Holdings, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this March 13, 2025.

/s/ Ian Hodgson

By: Ian Hodgson
